

How can genomics benefit your cancer patients?


Knowing a tumor's genetic fingerprint can aid in the diagnosis and prognosis of cancer and help inform treatment decisions.

Learn more about SearchLight DNA[™], an extensively validated diagnostic test from Vidium Animal Health[®] that uses next-generation sequencing to identify important mutations in 120 relevant cancer genes.

<image>

Discover how SearchLight DNA can provide insights into a cancer's origin, its behavior, and the optimal approach to treatment. How does SearchLight DNA" work?

Once your patient's tumor sample arrives at our genomics laboratory, Vidium scientists extract and sequence the DNA, and analyze each tumor's genome to identify its unique mutations. We then use our proprietary biomarker database, Vidium Insight[™], to bring the latest diagnostic, prognostic, and treatment guidance to each case.



Why run a tumor panel?

- :: Mutations in one tumor may not be present in another tumor of the same histology
- :: Most tumors evaluated by Vidium Insight have mutations with diagnostic, prognostic, and therapeutic actionability
- C ther tumors may have inferred actionability that can guide the use of targeted therapy

SearchLight DNA is backed by unimpeachable science

In a validation study, SearchLight DNA demonstrated:

- :: 95% sensitivity and 99% specificity for detection of low allele frequency (AF), single nucleotide variants (SNVs), and internal tandem duplications (ITDs)¹
- :: Reproducibility ≥95%¹
- :: Zero cross-contamination¹
- : High performance across tissue and tumor types¹





for detection of low AF SNVs and ITDs¹

5 THINGS TO KNOW ABOUT SEARCHLIGHT DNA

- 1. SearchLight DNA is a rigorously validated test.
- 2. As a descriptive panel, SearchLight DNA provides a new layer of comprehensive information about a pet's cancer so that *you* can make the best decisions for your patient and client.
- 3. SearchLight DNA is driven by our extensive database, Vidium Insight, which includes all the updated, curated, and pertinent information surrounding genomics in cancer, as well as extensive mutation data and clinical outcomes data.
- 4. Our in-house laboratory evaluates tumors without making assumptions on histology; genes and mutations are evaluated consistently.
- 5. Test results are summarized in a report highlighting the specific mutations found within that tumor.

When should you use SearchLight DNA[™]?

SearchLight DNA can be used for *any* case in which you and your client want all possible information on a tumor. This includes common canine cancers, such as mast cell tumors, lymphomas, and osteosarcomas. The test is also useful for identifying targeted therapy options for a particular case.

SEARCHLIGHT DNA IS PARTICULARLY USEFUL FOR THESE CASES

| CASES | EXAMPLE |
|---|---|
| Poorly differentiated tumors | Undifferentiated round cell tumors |
| Tumors with an uncertain diagnosis | Amelanotic melanoma vs oral sarcoma |
| Tumors in uncommon locations | Mammary melanoma or retropharyngeal hemangiosarcoma |
| Tumors in which a standard of care does not currently exist | Splenic liposarcoma |
| Tumors in which there are no effective chemotherapy treatment options | Metastatic hemangiosarcoma |
| Tumors that have progressed despite standard-of-care treatment | Apocrine gland anal sac adenocarcinoma with local or distant progression |
| Metastatic lesions in unexpected or uncommon locations | Thyroid carcinoma that metastasized to the spleen |
| Pet owner preference | Pet owners who do not want to pursue injectable chemotherapy, preferring oral therapy options |

Summary of relevant drug information to guide treatment

We collect all available information on any targeted drugs that match identified canine tumor mutations, including:

: Pharmacokinetics

Safety and/or dosing


:: Toxicology

: Drug resources

We also have strategic collaborations with institutions to conduct genomic and drug clinical trials.

Information on your patient's tumor is powered by Vidium Insight[™]

Vidium Insight is a proprietary knowledge database, combining extensive literature, mutation, and outcomes databases. To date, Vidium Insight has curated from...



...and these numbers will only increase!

What samples are needed to run a SearchLight DNA[™] test?

SearchLight DNA can be run on samples submitted in the following forms and quantities:

| FINE-NEEDLE ASPIRA | TE (FNA) SAMPLES |
|--------------------------|--|
| FNA SLIDES | >5 unstained or stained slides with 1 Diff-Quik slide |
| FNA LIQUID | >0.5 mL in sterile vial/tube with no additives |
| BIOPSY SAMPLES | |
| FFPE SCROLLS | 10 x 10-micron sections with 1 adjacent H&E slide |
| UNSTAINED FFPE SLIDES | 10 x 10-micron sections with 1 adjacent H&E slide |
| BONY TUMOR | Please submit a non-decalcified sample or allow us to coordinate with the pathology lab to select an appropriate sample. |

FFPE = formalin-fixed, paraffin-embedded H&E = hematoxylin and eosin





What information is contained in a SearchLight DNA report?

Veterinarians who order SearchLight DNA will receive a complete report 9–12 days after the tumor sample arrives at our laboratory. Information contained in each report includes:

- :: Genomic mutation information, including diagnostic, prognostic, and therapeutic biomarkers
- :: A list of targeted therapeutic drug(s), if the patient's tumor mutations are a match for an existing drug
- : Pharmacologic marker (MDR1) mutation status with gene summary
- Clinical trials available for the patient's cancer type
- : References
- :: Assay description and genes/mutations evaluated

| JF. 504 | 1 Vet Specialty + Emergency gan Howard | Texture | Accession: V12 | 1.415 |
|----------------------------|--|--|--|-------|
| | | | | |
| W | Ne dava tanin MORY David Barls Dagenia Putrosan Almanantana | Anat Are CaliforDaude Penale | Apr Ann Thy Long | |
| | | | | |
| | Light DNA Overview | | | |
| | ra Identified 4 | Reading of Challer Trade | | |
| ionati | | Number of Clinical Trails This Cancer Tree: | | |
| 8883 | p.Valid20a Julia 33e | General Cancer | ÷ | |
| 81 | Com Number Loss | | | |
| 713 | a And 2000 m | A Descela Bornet | | |
| | proposed of | <u> </u> | | |
| - | Ratio | 😨 2 Programis Biomati | mil. | |
| Apartment Apar 1979 hourse | | 2 Matching Drugs Lapatinis, Neratinis | | |
| an bege | the angle (a mail) where | · · · · · | | |
| | | | | |
| | Light DNA Summary | | | |
| | | | | |
| | adiasted GC sense provide Mildy's lower sample. The A It is written's in manufacture ARCHI, Maniated adjance effe | | | - |
| | oported in samon pulmonary adenosaminoma, supporter | g its pathologic diagramit. | | |
| | ter EXUED (alos losser as Herd) alteration tris samer me Leally, this 1942 splice site alteration has been associated opening plan. | y ie sensitor is ten 2008.) shisto althousidene is Turnelnik, warm | drugs, Lapatinis and ling sensitienation in | |
| | en skilar så annel, somandelar adipholog elli. Dones slokar dveril intenkon ligular Norse av avannel dat, intension som en somane ausur manna, si ormenale mante sellin til | n lumin el niscitorgila, lermentare un nan letin. End bragat magna a mile a | negat jain negat. ain, na mila ana | |
| | ensentellar sostettingan metion, vilan possare en familiek a arte nella sempar sonos, fammar scenar assentation litere e neu materias, Galance meti socia sitan metio litere | r ut annuman, in han halifanne plat eilinheim. Nulle bhimer inning error | | |
| lecieuse fae sais | | r burley | | |
| lecieuse fae sais | r nu intentum et malesuatie lames au ante ipsum primis i | | | |
| ní nu ur lar sait | r nu. Intendum of malescania lames an ante ipsum primis i | | | |













Vidium offers exceptional customer service

Vidium is available at every step of the process—from order to sample processing to post-report. We will do all the legwork in getting the samples from your lab or another pathology lab. Medical oncologists, pathologists, and genomic scientists are all on staff to answer any questions you have.

ABOUT VIDIUM ANIMAL HEALTH®

Vidium is dedicated to providing veterinarians with the very best technology and insight to confidently diagnose and treat pets with cancer.

We are proud to be incubated within the Translational Genomics Research Institute (TGen, an affiliate of City of Hope), a leader in the genomics revolution committed to advancing areas of genetics in human and animal health.





Join us in creating a better tomorrow for dogs with cancer. Learn more about SearchLight DNA[™] at www.vidiumah.com

Reference: 1. Wong S, Warrier M, Byron S, et al. Design, analytical validation and diagnostic yield of a novel canine cancer gene sequencing panel. Poster presentation at the Veterinary Cancer Society 2020 Annual Conference; 2020.

SearchLight DNA is a trademark of TGen Corporation. © Copyright 2021 Vidium Animal Health® 09/21 413671